Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubenimex (Bestatin) plus chemotherapy in metastatic breast cancer: real-world observational study
ChiCTR2200060145Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ubenimex in breast cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Progression-free survival and Quality of life score changes. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
ubenimex
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200060145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060145.